Breaking News, Collaborations & Alliances

Curis Achieves LLS Milestone

Will begin Phase I trials of CUDC-907

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Curis, Inc. has achieved the first two development milestones under its agreement with The Leukemia & Lymphoma Society (LLS) for the development of CUDC-907, triggering a $750,000 milestone payment. CUDC-907 is an orally-administered small molecule drug candidate inhibitor of phosphatidylinositol-3-kinase (PI3K) and histone deacetylase (HDAC). The milestones include a preclinical development target, as well as Curis’ IND filing to begin Phase I testing of CUDC-907. “The completi...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters